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Background & objectives: Infection with group A Streptococcus (GAS) may result in a number of human
diseases ranging from the relatively benign pharyngitis to the potentially life-threatening invasive
diseases and post-infectious sequelae. We have previously defined a minimal B-cell epitope from the
conserved region of the M-protein.  Here we report on the immunogenicity, opsonic potential of the
resulting sera and the level of protection induced by this peptide in comparison to a pepsin extract of
the M protein.
Methods: Inbred mice were immunized with peptides derived from the M protein. Sera were collected
from the immunized mice and its opsonic potential determined for M1 and M6 GAS strains. Mice were
then intranasally challenged with a virulent M1 GAS strain to determine the protective efficacy of the
peptides.
Results: The peptides induced significant antibody responses when delivered subcutaneously and
immunized mice demonstrated significantly enhanced survival compared to control groups following
challenge.
Interpretation & conclusion: The data obtained in the present study indicated that the chimeric peptide
J8 from the conserved region of the M protein could form the basis for an anti-streptococcal vaccine in
future.
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Infection with group A Streptococcus (GAS) may
result in a number of human diseases ranging from the
relatively benign pharyngitis to the potentially life-
threatening invasive diseases and post-infectious
sequelae, such as rheumatic fever (RF) and rheumatic
heart disease (RHD). The resurgence in severe invasive
disease and increased incidence of GAS infection, in
combination with the dynamic epidemiology of GAS
serotypes highlight the need to develop a safe, broad-
based, efficacious vaccine against this bacterium1.
We have previously described a 20-mer peptide
(p145) from the conserved region of the M protein which
induced antibodies in vaccinated mice that opsonised
multiple serotypes of GAS2,3. We also demonstrated that
the prevalence of p145-specific antibodies amongst
humans living in GAS-endemic areas increased with age
being found in approximately 40 per cent of children and
over 90 per cent  of adults4 - possibly increasing in
parallel with the acquisition of natural immunity to GAS.
We also demonstrated that affinity-purified human
antibodies to p145 could directly opsonise multiple strains
of GAS in vitro4,5.
Peptide p145 would be a vaccine candidate except
for the fact that humans may develop cross-reactive
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T cells to this region of the M protein6. We therefore
determined the minimal antibody epitope from the
p145 peptide and separated this from  any potential
deleterious T cell epitope. We previously determined
that the protective epitope in p145 was conformational
with alpha helical propensity7 a technique was
developed to  map the epitope by embedding small
peptides from p145 within other longer and unrelated
peptides which were also known to form a helical
coil.
These peptides, referred to as chimeric peptides,
maintained the appropriate tertiary structure, and
enabled us to map the minimal antibody epitope. The
antibody epitopes recognised by endemic human sera
were chimeric peptides J2, J7 and J84, whereas the
chimeric peptides recognised by p145 murine antisera
were J7 and J87,8. Human T cells respond to J2 and
murine T cells from B10.BR mice immunized with p145
respond vigorously to J38.  The aim of this study was
to compare the immunogenicity and protective potential
of our chimeric peptide (J8) with p145 and a pepM
extract.
Material & Methods
Peptide synthesis: Synthetic peptides were produced
as described9 and were purified by HPLC. The peptide
sequences for the p145 and J8 peptides are LRRD
LDASREAKKQVEKALEC and QAEDKVKQ
SREAKKQVEKALKQLEDKVQ respectively.
Immunization of mice: Peptides were administered
subcutaneously  in a volume of 50µl at the tail base to
B10.BR (inbred, H-2k) mice (Animal Resources Centre,
Western Australia).  Each mouse received a total of
30µg of immunogen emulsified 1:1 in  complete Freund’s
adjuvant (CFA) (Difco, USA). Mice were also given
subsequent booster injections at days 21, 31 and 41 post-
primary immunization.
Serum collection: Blood was collected from mice via
the tail artery and allowed to clot at 37oC for at least
30 min. Serum was collected after centrifugation at
1000 g for 10 min, heat inactivated at 56oC for 10 min
and stored at -20oC. Serum was collected from all of
the mice 1-day prior to boosts and 15 days after the
final boost.
Detection of murine antibodies: An ELISA was used
to measure J8-specific murine serum IgG antibodies and
the antibody isotypes were determined as described2,8.
Titre was defined as the highest dilution that gave an
optical density (OD) reading of more than three standard
deviations (SD) above the mean OD of control wells
containing normal mouse sera.
Indirect bactericidal assay: Murine anti-peptide sera
were assayed for their ability to opsonise GAS in vitro
as previously described2,4,5,10. Briefly, bacteria were
grown overnight at 37oC in 5ml Todd-Hewitt broth
(THB). GAS was then serially diluted to 10-5 in
phosphate-buffered saline (PBS).  For each individual
mouse, 50µl of fresh heat-inactivated serum was mixed
with 50µl of the bacterial dilution and incubated for
20 min at room temperature. After the incubation, 400µl
of non-opsonic heparinised human donor blood was
added. All donor blood was pre-screened prior to
performing the assay to ensure that it could support the
growth of the GAS strain by at least 32 times the
inoculum in a 3 h incubation at 37oC.
The mixtures were incubated end-over-end at 37oC
for 3 h and 50µl from each tube was plated out in
duplicate on 2 per cent blood THB agar pour plates.
The plates were incubated overnight and the number of
colonies on each plate was determined. Opsonic activity
of the anti-peptide sera [% reduction in mean colony
forming units (cfu)] was calculated as [1-(cfu in the
presence of anti-peptide sera) / (mean cfu in the presence
of normal mouse sera)] X 100.
Intranasal GAS challenge procedure: GAS was
cultured overnight in THB with 1 per cent neopeptone
and 200 mg/ml streptomycin, spun at 1500 g for 10 min
and washed twice with THB containing 1 per cent
neopeptone and resuspended in 25 per cent of the original
volume. The inoculum dose (cfu/ml) was determined by
optical density at 600nm and plating out 10-fold dilutions
of bacterial suspensions on 2 per cent  horse blood THB
agar plates. Following overnight incubation of the plates
at 37oC, colony counts were determined.  Immunized
and control mice were challenged intranasally with a
pre-determined dose of GAS in 30 µl (15 µl/nare).
Statistical analysis: The T-tests, mean and the standard
error of the mean were calculated using standard
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formulae. The log rank or Mantel-Haenszel test was
used to compare survival curves of challenged mice11.
P< 0.05 was considered significant.
Results
Inbred B10.BR (H-2k) mice were immunized with
the conserved region peptide p145 and its chimeric
derivative J8. Control mice received PepM extract or
PBS in CFA. The mice developed strong antigen-specific
serum IgG titres (Fig.1). IgG isotypes were
predominantly the IgG2a > IgG1 > IgG2b for both the J8
and p145 peptide. However for the pepM extract
IgG1was the predominant isotype followed by IgG2a and
IgG2b (data not shown). While IgA was not detectable
in the serum, antigen-specific serum IgM was shown to
be present albeit 5-fold lower then IgG1.
Serum collected from the immunized mice was
capable of the in vitro opsonisation of the M1 GAS
strain (Fig.2).  Mice immunized with p145 (P < 0.001),
J8 (P < 0.01) and pepM (P < 0.001) had significantly
higher levels of opsonisation when compared to the PBS
control group. Interestingly, serum from both peptide
(p145 and J8) immunized mice was capable of the
in vitro opsonisation of M1 GAS strain at similar levels
to that of the pepM mice (P>0.05). The antiserum was
also shown to opsonise the M6 GAS strain at similar
levels to that observed for the M1 strain (data not
shown).
Mice were then challenged intranasally with the M1
GAS strain (Fig.3). Mice immunized with p145 (P < 0.05),
J8 (P < 0.05) and pepM (P < 0.05) had significantly
higher levels of survival compared to the PBS/CFA
immunized mice. There was no significant difference in
survival in the p145, J8 and pepM immunized groups,
indicating the conserved region peptide was able to induce
protection equal to that of the pepM immunized mice.
Discussion
This study was carried out to determine the
immunogenicity of a conserved M protein epitope, J8, with
CFA and compare the levels of opsonisation and protection
induced by immunization with the parent peptide p145 and
the M protein extract pepM.  It was demonstrated that J8
induced significant antibody responses when delivered
Fig. 1. Antigen-specific serum IgG titres of immunized mice taken at
day 56 post-primary immunization. Horizontal bar indicates average.
PBS, phosphate buffer saline.
Fig.2. Average per cent opsonisation of an M1 GAS strain by serum
taken at day 56 post-primary immunization. PBS, phosphate buffer
saline.
Fig.3. Per cent survival of immunized mice following intranasal
challenge with an M1 GAS strain.
INDIAN J MED RES (SUPPL) MAY 2004
107
subcutaneously and that immunized mice demonstrated
significantly enhanced survival compared to control groups.
J8 when administered with CFA can protect up to 80
per cent  of H-2k responder strain mice (B10.BR) from
virulent challenge12. However, minimal epitopes such as
J8 are unlikely to be immunogenic in an outbred population.
To render such epitopes immunogenic they must be
conjugated to carrier proteins capable of inducing T cell
help. Diphtheria toxoid (DT) has been used as a carrier
protein in many systems and preliminary data from our
own laboratory suggested that anti-DT antibodies may in
fact be capable of opsonising GAS making DT an obvious
choice for a carrier protein for J8 in future studies.
The mechanism for J8 mediated protection of mice
from GAS challenge has not been completely defined.
However it has been demonstrated that the N-terminal
epitopes of the M protein induce high levels of serum
antibodies, which are highly opsonic to the corresponding
GAS strain13-15. These epitopes have also been shown
to induce high levels of protection from GAS challenge
in mice12, indicating that protection is antibody mediated.
In conclusion, the findings of the present study showed
that our peptide from the conserved region of the M protein
could form the basis of an anti-streptococcal vaccine.
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